HighVista Strategies LLC Makes New Investment in CytomX Therapeutics, Inc. $CTMX

HighVista Strategies LLC purchased a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 257,148 shares of the biotechnology company’s stock, valued at approximately $820,000.

Several other hedge funds and other institutional investors have also made changes to their positions in CTMX. Orbimed Advisors LLC purchased a new stake in CytomX Therapeutics during the 2nd quarter worth approximately $19,208,000. Commodore Capital LP purchased a new position in CytomX Therapeutics in the 2nd quarter valued at approximately $17,462,000. Perceptive Advisors LLC purchased a new position in CytomX Therapeutics in the 2nd quarter valued at approximately $15,876,000. Franklin Resources Inc. acquired a new position in shares of CytomX Therapeutics in the second quarter worth $13,096,000. Finally, Vivo Capital LLC acquired a new position in shares of CytomX Therapeutics in the second quarter worth $13,096,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 expansion data show solid activity in late‑line colorectal cancer — confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and manageable safety with ongoing dose optimization. Management is targeting mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Continues to Demonstrate Positive Data
• Positive Sentiment: Analyst upgrades and higher price targets lifted sentiment — HC Wainwright raised its target to $17 (buy) and JPMorgan upgraded CTMX to overweight with a $12 target; Seeking Alpha and Benzinga published bullish takes tying valuation to Varseta‑M’s late‑line mCRC opportunity. These notes reinforced upside expectations. Mid‑Cap CytomX Therapeutics’ Colorectal Cancer Data Fuels Stock Rally
• Neutral Sentiment: Market reaction and high trading volume: CTMX experienced unusually heavy volume and a large pre‑market move as headlines circulated and investors digested the clinical readout plus analyst commentary. That amplifies intraday volatility but is informational rather than fundamental by itself. Why CTMX Stock Is Soaring Pre‑Market
• Negative Sentiment: Proposed $250M underwritten public offering of common stock and pre‑funded warrants — the financing will be dilutive and typically weighs on near‑term per‑share metrics despite extending the cash runway for development. CytomX Announces Proposed Public Offering
• Negative Sentiment: Q4 miss on EPS and revenue — CTMX reported a ($0.22) EPS vs. consensus (~$0.08 loss) and revenue well below estimates, reinforcing near‑term cash burn and highlighting the company remains pre‑commercial. These fundamentals contrast with the positive clinical news. CTMX Reports Q4 Loss, Misses Revenue Estimates

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CTMX. Oppenheimer reiterated an “outperform” rating and issued a $12.00 price objective on shares of CytomX Therapeutics in a research note on Monday. Piper Sandler boosted their target price on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Barclays upped their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $7.00 to $12.00 in a research report on Monday. Finally, HC Wainwright boosted their price objective on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.88.

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX opened at $6.75 on Tuesday. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 16.88 and a beta of 2.44. The business has a 50-day moving average of $5.24 and a two-hundred day moving average of $4.07. CytomX Therapeutics, Inc. has a 1 year low of $0.40 and a 1 year high of $8.21.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.